Related references
Note: Only part of the references are listed.Global prediction of primary liver cancer incidences and mortality in 2040
Chenxi Li et al.
JOURNAL OF HEPATOLOGY (2023)
Glycogen storage in a zebrafish Pompe disease model is reduced by 3-BrPA treatment
Cinzia Bragato et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2020)
Pompe disease: what are we missing?
Benedikt Schoser
ANNALS OF TRANSLATIONAL MEDICINE (2019)
Pharmacokinetics and tissue distribution of 3,4-diaminopyridine in rats
Natsuko Ishida et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2019)
Analysis of tail coiling activity of zebrafish (Danio rerio) embryos allows for the differentiation of neurotoxicants with different modes of action
Florian Zindler et al.
ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY (2019)
Italian recommendations for diagnosis and management of congenital myasthenic syndromes
Lorenzo Maggi et al.
NEUROLOGICAL SCIENCES (2019)
Drug repurposing: progress, challenges and recommendations
Sudeep Pushpakom et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia
Donald B. Sanders et al.
MUSCLE & NERVE (2018)
A beginner's guide to understanding and implementing the genetic modification of zebrafish
Sara A. Rafferty et al.
PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY (2018)
Zebrafish: an emerging real-time model system to study Alzheimer's disease and neurospecific drug discovery
Suraiya Saleem et al.
CELL DEATH DISCOVERY (2018)
Amifampridine phosphate in the treatment of muscle-specific kinase myasthenia gravis: a phase IIb, randomized, double-blind, placebo-controlled, double crossover study
Silvia Bonanno et al.
SAGE OPEN MEDICINE (2018)
Zebrafish as a Model to Investigate Dynamin 2-Related Diseases
Cinzia Bragato et al.
SCIENTIFIC REPORTS (2016)
INaP selective inhibition reverts precocious inter- and motorneurons hyperexcitability in the Sod1-G93R zebrafish ALS model
Lorena Benedetti et al.
SCIENTIFIC REPORTS (2016)
Correcting Neuromuscular Deficits With Gene Therapy in Pompe Disease
Adrian G. Todd et al.
ANNALS OF NEUROLOGY (2015)
Peripheral nerve and neuromuscular junction pathology in Pompe disease
Darin J. Falk et al.
HUMAN MOLECULAR GENETICS (2015)
The European LEMS Registry: Baseline Demographics and Treatment Approaches
Renato Mantegazza et al.
NEUROLOGY AND THERAPY (2015)
Enzyme replacement therapy and fatigue in adults with Pompe disease
Deniz Gungor et al.
MOLECULAR GENETICS AND METABOLISM (2013)
Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria
Thomas P. Mechtler et al.
LANCET (2012)
Fiji: an open-source platform for biological-image analysis
Johannes Schindelin et al.
NATURE METHODS (2012)
Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial
S. Strothotte et al.
JOURNAL OF NEUROLOGY (2010)
Efficacy of 3,4-Diaminopyridine and Pyridostigmine in the Treatment of Lambert-Eaton Myasthenic Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study
P. W. Wirtz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Reversal of Cardiac Dysfunction after Enzyme Replacement in Patients with Infantile-Onset Pompe Disease
Lei-Ru Chen et al.
JOURNAL OF PEDIATRICS (2009)
Loss of Myotubularin Function Results in T-Tubule Disorganization in Zebrafish and Human Myotubular Myopathy
James J. Dowling et al.
PLOS GENETICS (2009)
Lysosomal storage disease 2 - Pompe's disease
Ans T. van der Ploeg et al.
LANCET (2008)
Therapeutic approaches in glycogen storage disease type II/Pompe disease
Benedikt Schoser et al.
NEUROTHERAPEUTICS (2008)
Treatment with sodium benzoate leads to malformation of zebrafish larvae
Huey-Jen Tsay et al.
NEUROTOXICOLOGY AND TERATOLOGY (2007)
Fatigue: an important feature of late-onset Pompe disease
Marloes L. C. Hagemans et al.
JOURNAL OF NEUROLOGY (2007)
A guided tour into subcellular colocalization analysis in light microscopy
S. Bolte et al.
JOURNAL OF MICROSCOPY (2006)
Characterization of pre- and post-treatment pathology after enzyme replacement therapy for pompe disease
Beth L. Thurberg et al.
LABORATORY INVESTIGATION (2006)
Long term intravenous treatment of Pompe disease with recombinant human α-glucosidase from milk
JMP Van den Hout et al.
PEDIATRICS (2004)
Enzyme replacement therapy in the mouse model of Pompe disease
N Raben et al.
MOLECULAR GENETICS AND METABOLISM (2003)
Effective targeted gene 'knockdown' in zebrafish
A Nasevicius et al.
NATURE GENETICS (2000)
Share Paper
